DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics. The concept of DNA diagnostics has evolved via the breakthrough human genome project that resulted in the discovery of various disease-causing agents. The DNA diagnostics market is expected to generate 19 billion by 2020, growing at a CAGR of 9.8% during the analysis period. Technological development has played a major role in improving DNA diagnostic platforms and techniques.
Some of the significant technologies which incorporate DNA diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry; these technologies are used for sample preparation, DNA isolation etc. Technological developments, which have led to improvements in these methodologies, drive the growth of the DNA diagnostics market. The use of DNA diagnostic methods in prenatal diagnostics and clinical confirmation has also boosted market growth. The DNA diagnostics market is expected to experience a growth spurt in the foreseeable future. Innovations in product design and technology have prompted doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. The increased adoption of the personalized medicines approach would positively impact the DNA diagnostics market in the foreseeable future. Next generation sequencing is a powerful tool for decoding a number of human diseases, including various forms of cancer. Next generation sequencing reduces the cost of sequencing and increases the throughput. The optimization of sequencing technology could greatly impact the DNA diagnostics market.
The report breaks the market into segments based on product type, technology, application, end users and geography. Based on product types, the market is segmented into instruments, reagents and service & software. The instruments segment holds the dominant share in the market, due to improved healthcare facilities, availability of user-friendly instruments, its competitive cost structure, reliability, size and the growing demand for it in the DNA diagnostics market. However, the service & software segment is expected to grow at a steady rate in the near future due to technological advancements and the incorporation of information technology in the DNA diagnostics market. There are several technologies used in the DNA diagnostics market; these include PCR, mass spectrometry, sequencing technology, in-situ hybridization and microarrays. PCR holds the dominant share due to its frequent usage in diagnostic procedures such as sample preparation, separation and isolation of DNA from collected samples. The DNA diagnostics market is also segmented based on its application in various diseases such as oncology, infectious diseases and myogenic disorders. The oncology segment leads the market and is followed by infectious diseases due to the rising incidence of these diseases and growing elderly population. In terms of geography, the market is segmented into North America, Asia Pacific, Europe and LAMEA. North America holds the dominant share in the market due to the increased adoption of the DNA diagnostics technology and the high prevalence of chronic and infectious diseases. Companies profiled in the report include Roche Diagnostics, Bayer Diagnostic, Sysmex, Abbott laboratories, Gene-probe Inc., Cephide, Illumina, Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Johnson and Johnson, and Novartis.
The DNA diagnostics market is segmented based on product type, technology, application, end users and geography
MARKET BY PRODUCT TYPE
MARKET BY TECHNOLOGY
MARKET BY APPLICATION
MARKET BY END USERS
MARKET BY GEOGRAPHY
SIMILAR MARKET STUDIES
2017 New Zealand Hematology and Flow Cytometry Markets: Specimen, Sales and Volume Forecasts for 40 Tests, Competitive Strategies, Instrumentation Review, Technological Advances, Opportunities for Suppliers
Summary This new comprehensive report from VPGMarketResearch.com contains 225 pages and 5 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities during the next five years. The report explores business and technological trends; provides specimen, sales and volume forecasts for 40 tests; compares ...
January 2017 | $0 | View Details >>
This new report from VPGMarketResearch provides strategic assessments of major cancer diagnostic product suppliers and emerging market entrants. The report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 80 pages
September 2015 | $0 | View Details >>
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to ...
September 2015 | $2800 | View Details >>
This report studies sales (consumption) of Cardiac POC Testing Devices in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Alere Inc. Abbott Laboratories Roche Diagnostics Beckman ...
August 2016 | $4900 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research